The specification of hematopoietic stem cells (HSCs) in vertebrate embryos is tightly regulated by RNA polymerase II (Pol II)-mediated transcription, which proceeds through multiple steps including initiation/activation, elongation and termination. Understanding the transcriptional mechanism of HSC development provides significant insight into the pathophysiology of human blood diseases. Extensive studies in recent years have demonstrated that transcriptionally engaged Pol II often stalls at 20-40bp downstream of the promoter. This promoter-proximal pausing of Pol II is mediated by pausing factors DSIF and NELF, and requires the positive elongation factor P-TEFb for release. Disrupted pausing-to-elongation switch often causes cell-specific defects, suggesting a role of Pol II pausing in cell fate determination. In line with this, my previous work showed that disruption of Pol II elongation specifically blocked the differentiation of erythroid progenitors in zebrafish embryos. In this proposal, I extend the work to explore how the pausing-to-elongation transition contributes to cell fate determination of HSCs, and which signaling pathways regulate this process. We have used zebrafish genetics to demonstrate that embryonic HSC development requires a well-controlled release of paused Pol II. Loss of pausing factors NELF or DSIF causes significant reduction of HSCs, which can be restored by reducing Pol II elongation via inhibition of P-TEFb activity. Using biochemical approaches, we have identified proteins that potentially facilitate Pol II pausing and elongation by interacting with pausing factors. Furthermore, we have performed a chemical screen to rescue the HSC defect in pausing-deficient zebrafish embryos and identified multiple compounds involved in distinct signaling pathways. Based on these preliminary data, we hypothesize that a tightly controlled Pol II elongation cooperates with transcription regulators and developmental signals to regulate HSC emergence in vertebrate embryos. We will test this hypothesis using an integrated approach with a complementary set of model systems including both zebrafish and human blood cell culture systems.
Aim 1 will use a combination of genetic, genomic and biochemical approaches to determine the mechanisms by which Pol II pausing factors regulate HSC formation and identify primary HSC targets regulated by Pol II pausing.
In Aim 2, we will identify interacting partners cooperating with DSIF to control Pol II pausing on hematopoietic genes.
Aim 3 will focus on the functional interplay between steroid hormone receptor signaling pathways and the Pol II pausing/elongation machinery during HSC development. Completion of these aims will provide important insights for understanding the developmental role of Pol II pausing and also allow us to identify novel regulators of HSC specification. Given the involvement of disregulated transcription elongation in a variety of human disorders, these studies will advance our understanding of its role in the pathogenesis and progression of these maladies and may also identify candidate genes or pathways that can be used for developing novel targeted treatment strategies.

Public Health Relevance

Greater insight into the regulation of hematopoietic stem cell generation will lead to improved treatment for blood diseases caused by ineffective hematopoiesis. By studying the detailed regulatory mechanisms that precisely control HSC gene expression in developing vertebrate embryos, my research will advance our understanding of the mechanisms that controls blood formation and may identify novel regulators that will broaden possible therapeutic targets for blood diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK105287-03
Application #
9262222
Study Section
Molecular and Cellular Hematology Study Section (MCH)
Program Officer
Bishop, Terry Rogers
Project Start
2015-04-01
Project End
2020-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
3
Fiscal Year
2017
Total Cost
$318,736
Indirect Cost
$116,236
Name
University of Texas Sw Medical Center Dallas
Department
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Tastemel, Melodi; Gogate, Aishwarya A; Malladi, Venkat S et al. (2017) Transcription pausing regulates mouse embryonic stem cell differentiation. Stem Cell Res 25:250-255
Liu, Xiuli; Gogate, Aishwarya A; Tastemel, Melodi et al. (2017) Dynamic Change of Transcription Pausing through Modulating NELF Protein Stability Regulates Granulocytic Differentiation. Blood Adv 1:1358-1367
Yang, Qiwen; Liu, Xiuli; Zhou, Ting et al. (2016) RNA polymerase II pausing modulates hematopoietic stem cell emergence in zebrafish. Blood 128:1701-10
Liu, Xiuli; Kraus, W Lee; Bai, Xiaoying (2015) Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathways. Trends Biochem Sci 40:516-25